🔬 What This Document Is

This is a 6-K filing from Tiziana Life Sciences, which is essentially a report the company files with the SEC to share important news with investors. The attached press release announces new preclinical (lab study) data for their drug candidate, intranasal foralumab.

👉 In simple terms: It's an update telling the world that early research shows their nasal spray drug might help improve brain function affected by aging.

🧠 What The Company Does

Tiziana Life Sciences is a clinical-stage biopharmaceutical company. Their entire focus is on developing new therapies using a unique delivery method: spraying drugs into the nose.

👉 In simple terms: They are a biotech company trying to treat brain diseases by using the nose as a direct delivery route to the brain, which they believe is safer and more effective than traditional IV infusions.

🔬 The Big Discovery: Fighting Brain Aging

The press release shares results from an animal study on aging. Their drug candidate, nasal anti-CD3 (foralumab), showed promising effects.

Key Findings:

• 🧯 Dampens Brain Inflammation: The drug reduced the activity of microglial cells, which are the brain's immune cells that can cause chronic inflammation linked to cognitive decline.
• 🌱 Boosts Brain Repair: It increased neurogenesis (the birth of new brain cells) in the hippocampus, the brain's memory center.
• ⏳ Reduces Cell Aging: The drug also lowered markers of cellular senescence (biological aging).

👉 Why it matters: This suggests the drug's mechanism isn't just managing symptoms, but could potentially slow or reverse some core biological processes of brain aging.

💡 Why This Is a Big Deal

This data suggests a potential new use for foralumab. While Tiziana is already testing it for diseases like Multiple Sclerosis and Alzheimer's, this research points to a broader application in age-related cognitive decline.

Dr. Howard Weiner, the company's Scientific Advisory Board Chair, highlights that it's a "non-invasive approach" that works by regulating the immune system to repair the brain.

🚀 What's Next for Tiziana

This preclinical finding supports their ongoing work but doesn't change their immediate clinical plans. The company is actively advancing foralumab in several mid-stage trials:

• Non-Active Secondary Progressive MS (na-SPMS): In an Expanded Access program, 14 patients showed improvement or stability after 6 months. A separate Phase 2a trial is also underway.
• Other Neurodegenerative Diseases: They have clinical programs for MSA (Multiple System Atrophy), ALS, and Alzheimer's disease.

👉 The path forward: They will use this promising aging data to potentially design future studies while focusing on pushing their current clinical trials forward.

🧪 The Delivery Method Advantage

A crucial part of Tiziana's story is their patented nasal delivery technology. By delivering the fully human anti-CD3 antibody through the nose, they aim to:

• Have a better safety and tolerability profile than intravenous (IV) delivery.
• Directly target the brain and central nervous system more effectively.
• Create a platform that could be used for a wide range of brain and immune diseases.

📅 Key Dates & Contacts

For ongoing updates and investor inquiries, the primary contact is:

• Investor Relations: +44 (0) 207 495 2379
• Email: [email protected]

⚖️ Strengths & Risks

👍 Potential Strengths:

• Novel mechanism targeting neuroinflammation.
• Differentiated, non-invasive nasal delivery method.
• A broad pipeline targeting multiple serious brain diseases.

⚠️ Key Risks:

• This is only preclinical data. The results seen in animals often do not translate to humans.
• The company is still in the clinical trial stage; none of its drugs are approved for sale yet.
• Developing biotechnology is extremely expensive and complex.

🧠 The Analogy

Think of Tiziana's drug like a specialized gardener for the brain. Instead of using harsh chemicals (strong IV drugs) that affect the whole body, this gardener uses a gentle, direct mist (nasal spray) to calm an overgrown, inflammatory "weed" (microglial activation) and encourage the growth of new, healthy "plants" (neurogenesis).

🧩 Final Takeaway

Tiziana Life Sciences released early research showing its nasal spray drug candidate could potentially reverse aspects of brain aging in animals by reducing inflammation and promoting repair. This is promising, foundational science that supports their ongoing work in neurodegenerative diseases, but it's a very long way from becoming a proven treatment for people.